Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03143543 · ClinicalTrials.gov registry record · Phase 1
Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 171
- Enrollment target
NCT03143543 is a Phase 1 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 171 participants.
The verdict
NCT03143543, a Phase 1 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 171 participants
- Enrollment target
Study Summary
The purpose of Project 2 is to execute phase I functional magnetic resonance imaging (fMRI) studies to assess the effects of lorcaserin on brain target engagement (measured by fMRI brain activation and neural connectivity) in cocaine use disorder (CocUD) subjects and/or opioid use disorder.
Interventions
- DRUG Group A Lorcaserin (10mg)
- DRUG Group A2 Lorcaserin (20 mg)
- OTHER Group B Parallel Placebo
- OTHER Group B2 Parallel Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-12-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03143543
The ClinicalTrials.gov registry entry for NCT03143543 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Group A Lorcaserin (10mg) is the first listed.
NCT03143543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03143543 about?
NCT03143543 is a clinical study titled "Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder". The purpose of Project 2 is to execute phase I functional magnetic resonance imaging (fMRI) studies to assess the effects of lorcaserin on brain target engagement (measured by fMRI brain activation and neural connectivity) in cocaine use disorder (CocUD) subjects and/or opioid use disorder.
What is the current status of trial NCT03143543?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 171 participants. The study started on 2015-07. Estimated completion is 2019-12-06.
What interventions are being tested in trial NCT03143543?
The interventions under investigation include: Group A Lorcaserin (10mg) (DRUG), Group A2 Lorcaserin (20 mg) (DRUG), Group B Parallel Placebo (OTHER), Group B2 Parallel Placebo (OTHER).
Who is sponsoring clinical trial NCT03143543?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.